ImmunityBio reports estimated cash and securities of $108M as of Dec 31, 2022

ImmunityBio, Inc.

Preliminary estimate of cash, cash equivalents and marketable securities as of Dec 31, 2022: approximately $108.0M.
Includes $104.6M cash & equivalents and $3.4M marketable securities.
These are preliminary estimates; final results may differ and will be in Form 10-K.

item 2.02

ImmunityBio, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-039399

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.